Worcester-MA
Worcester-MA-Mobile

Transthyretin Amyloidosis (ATTR)

RNA Therapeutics Symposium (RNATx) 2026

Congress Details

calanderJune 24-26, 2026

locationWorcester, MA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

26 June, 2026

Coming soon
icon Presentation Type
Poster
time icon Time
1:15 PM- 2:55 PM ET
location icon Location
Poster Session 1
icon Title
Transitioning APOLLO-B Participants to Ongoing RNAi Access Pathways: Operational Learnings in Moving Late Stage Programs into Real World Care
mic Presenter

Stephanie Skouras

Alnylam Pharmaceuticals

MA, USA

Related Materials

Transthyretin Amyloidosis (ATTR)

Gene Silencing Therapeutics in Cardiology: A Review Article

International Journal of Cardiovascular Sciences

Author(s)

Patrick Jay, Martin Maier, Laura Saltonstall, et al

September 2022

Transthyretin Amyloidosis (ATTR)

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

Amyloid

Author(s)

David Adams, Ivailo Tournev, Mark Taylor, et al

July 2022

Transthyretin Amyloidosis (ATTR)

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

American Journal of Transplantation

Author(s)

Hartmut Schmidt, Jonas Wixner, Violaine Planté-Bordeneuve, et al

June 2022

Transthyretin Amyloidosis (ATTR)

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

Circulation: Genomic and Precision Medicine

Author(s)

Barry Trachtenberg, Sachin Shah, Robert Nussbaum, et al

August 2021

Transthyretin Amyloidosis (ATTR)

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

The Lancet Neurology

Author(s)

David Adams, Michael Polydefkis, Alejandra González-Duarte, et al

November 2020

Transthyretin Amyloidosis (ATTR)

Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

Amyloid

Author(s)

Margaret M Parker, Simina Ticau, James Butler, et al

September 2020